DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER (DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER).
Dextrose is a carbohydrate that provides caloric support and prevents ketosis. Potassium chloride provides potassium ions for electrolyte balance and cellular function.
| Metabolism | Dextrose is metabolized via glycolysis and the citric acid cycle. Potassium is eliminated renally. |
| Excretion | Exclusively renal: >98% of potassium ion is excreted via kidneys, with minimal fecal loss. Dextrose is completely metabolized to CO2 and water, with no direct renal excretion of intact dextrose under normal conditions. |
| Half-life | Potassium: Terminal half-life approximately 4–6 hours in patients with normal renal function, but highly variable depending on glomerular filtration rate; up to 20–30 hours in severe renal impairment. Dextrose: Not applicable as it is rapidly cleared from blood via insulin-mediated uptake; metabolic half-life minutes. |
| Protein binding | Potassium: <0.1% bound to plasma proteins (minimal). Dextrose: Not protein bound. |
| Volume of Distribution | Potassium: Apparent Vd ~0.5 L/kg, representing distribution primarily in intracellular water (98% total body potassium is intracellular). Dextrose: Vd approximates total body water (~0.6 L/kg) as it distributes freely in extracellular and intracellular compartments via GLUT transporters. |
| Bioavailability | Intravenous: 100% bioavailability. |
| Onset of Action | Intravenous infusion: Correction of hypokalemia begins within minutes to 1 hour depending on infusion rate and degree of depletion; dextrose effect on blood glucose immediate upon infusion. |
| Duration of Action | Potassium effect persists for hours after infusion cessation, with duration proportional to dose and renal function; dextrose effect short-lived (1–2 hours) due to rapid metabolism and insulin response. |
Intravenous infusion: 5% dextrose and 0.224% potassium chloride at a rate of 100-200 mL/hour for maintenance fluid and electrolyte replacement, adjusted based on serum potassium levels and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR >50 mL/min: no adjustment. GFR 30-50 mL/min: reduce potassium content or monitor potassium closely. GFR <30 mL/min: use with caution; consider alternative potassium-free solutions or reduced potassium concentration due to risk of hyperkalemia. |
| Liver impairment | No specific adjustment required; use standard dosing with monitoring of electrolytes in hepatic impairment. |
| Pediatric use | Weight-based dosing: 5% dextrose with 0.224% KCl intravenous infusion at 2-4 mL/kg/hour for maintenance, adjusted based on weight, serum potassium, and clinical condition. Typical electrolyte replacement: 1-2 mEq/kg/day of potassium, titrated. |
| Geriatric use | Use with caution; start at lower infusion rates (e.g., 50-100 mL/hour) and monitor for fluid overload, hyperkalemia, and renal function. Adjust potassium content based on renal function and serum potassium levels. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER (DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose and potassium chloride are endogenous substances normally present in breast milk. Intravenous infusion of these components at standard concentrations does not significantly alter milk composition or pose risk to the infant. The M/P ratio is approximately 1.0 for both components, indicating equilibrium with maternal plasma. Breastfeeding is considered safe during maternal infusion, provided maternal electrolyte and glucose levels are maintained within normal limits. |
| Teratogenic Risk | Dextrose 5% and potassium chloride 0.224% infusion. Dextrose at standard doses is generally considered safe and not teratogenic; maternal hyperglycemia from excessive dextrose can increase fetal anomaly risk (neural tube defects, congenital heart defects) in first trimester, and risk of macrosomia, neonatal hypoglycemia in second/third trimesters. Potassium chloride at therapeutic infusion rates is not teratogenic; however, maternal hyperkalemia or hypokalemia can cause fetal arrhythmia or growth restriction. Overall, risk is minimal with appropriate monitoring. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria","Addison's disease","Crush injury or severe burns","Drugs causing potassium retention (e.g., ACE inhibitors, potassium-sparing diuretics)"]
| Precautions | ["Hyperkalemia risk if kidney function impaired or rapid administration","Hypokalemia if given without potassium monitoring","Fluid overload in patients with heart failure or renal impairment","Phlebitis at injection site"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium and glucose levels periodically during infusion to avoid hyperglycemia, hypokalemia, or hyperkalemia. Fetal heart rate monitoring is indicated if maternal electrolyte disturbances or fluid overload occurs, especially in preterm labor or preeclampsia. Assess for signs of fluid overload (edema, pulmonary congestion) and monitor urine output. |
| Fertility Effects | No direct adverse effects on fertility are expected from dextrose or potassium chloride at therapeutic doses. Indirect effects may occur if underlying maternal conditions (e.g., diabetes, renal impairment) affect fertility. No evidence of impairment in animal studies. |